

CHEMOTHERAPY PROTOCOL
Systemic Anti-Cancer Treatment At Home Nurse Handbook

GOSERELIN PROTOCOL

DOCUMENT REF: MCHAGOSER
(Version No. 1.1)

Name and designation of procedure author(s)	Dorothy Probert- Manager Clatterbridge in The Community
Approved by (committee, group, manager)	Dr. Carlo Palmieri – Consultant in Medical Oncology
Approval signature	Electronic approval received
Date approved	14 th January 2019
Review date	January 2020
Review type (annual, three yearly)	Annual
Target audience	Clinical Staff
Links to other strategies, policies, procedures	
Protective Marking Classification	Internal
This Document Replaces	V1.0

Issue Date: 14 th January 2019	Page 1 of 5	Filename: MCHAGOSER	Version No: 1.1
Author: Dorothy Probert	Authorised by: Dr. Carlo Palmieri	Copy No:	

Consultation:

	Authorised by	Date Authorised	Comments
Impact Assessment	N/A	N/A	N/A
Fraud Department	N/A	N/A	N/A

Circulation/Dissemination:

Date added into Q-Pulse	14 th January 2019
Date notice posted in the Team Brief	14 th January 2019
Date document posted on the intranet	14 th January 2019

Version History:

Date	Version	Author name and designation	Summary of main changes
Jan 2016	1.0	Frances Lawton - Project Manager; Chemotherapy Directorate	First version.
Jan 2019	1.1	Dorothy Probert-Manager Clatterbridge in The Community	No changes made

Issue Date: 14 th January 2019	Page 2 of 5	Filename: MCHAGOSER	Version No: 1.1
Author: Dorothy Probert	Authorised by: Dr. Carlo Palmieri	Copy No:	

Approved for use in

- Goserelin 3.6mg is approved for use in the treatment of breast cancer in the following settings:
 - Adjuvant and advanced breast cancer in pre and perimenopausal women suitable for hormonal manipulation in addition to other systemic anti-cancer therapy

Dosage

Breast Cancer

Drug	Dose	Route	Frequency
Goserelin	3.6mg	SC implant	Every 4 weeks with duration of treatment to be documented by Consultant

Supportive Treatments

None

Extravasation risk

None as given subcutaneously

Administration

Preparation

Provided in a pre-filled syringe

Day	Drug	Dose	Route	Notes
1	Goserelin	3.6mg	Implant	injected subcutaneously into the anterior abdominal wall

Considerations

- The injection site should be alternated between the left and right abdomen.
- Patients with known depression and patients with hypertension should be monitored carefully.

Issue Date: 14 th January 2019	Page 3 of 5	Filename: MCHAGOSER	Version No: 1.1
Author: Dorothy Probert	Authorised by: Dr. Carlo Palmieri		Copy No:

Main Toxicities

Goserelin

Decreased libido, Menopausal symptoms, Hyperhidrosis, Acne, Injection site hypersensitivity reaction, impaired glucose tolerance, mood changes and depression, cardiac toxicity, BP abnormality, rash, bruising can occur on skin

Investigations

No investigations are required

Dose Modifications and Toxicity Management

Dose reduction schedule

Dose reductions are not used to manage toxicity

Hypersensitivity

Hypersensitivity reactions are rare and should be managed as per The Clatterbridge Cancer Centre protocol. Injection site reactions are common

Caution should be exercised if taking anticoagulants, aspirin or gonadotrophins for fertility treatment. Check with doctor or pharmacist before using other medicines while being treated to make sure the combination is safe.

Read more: <http://www.netdoctor.co.uk/cancer/medicines/zoladex.html#ixzz3mexzYznG>

Follow us: [@NetDoctor on Twitter](#) | [NetDoctorUK on Facebook](#)

Medical review

- As per SACT action sheet in advanced disease
- At least 6monthly in adjuvant patients

Issue Date: 14 th January 2019	Page 4 of 5	Filename: MCHAGOSER	Version No: 1.1
Author: Dorothy Probert	Authorised by: Dr. Carlo Palmieri	Copy No:	

Nurse led review

Nurse review at each cycle including completion of the metastatic checklist for patients with advanced disease. If unacceptable toxicity, decline in performance status during treatment or intercurrent problems occur do not give the medicine before obtaining medical advice and refer back for medical review.

References:

BNF 68

Zoladex 3.6mg Implant SPC

Issue Date: 14 th January 2019	Page 5 of 5	Filename: MCHAGOSER	Version No: 1.1
Author: Dorothy Probert	Authorised by: Dr. Carlo Palmieri	Copy No:	